Loading patent…
AssigneesFundacio Privada Institutcio Catalana de Recerca I Estudis Avancats (ICREA), Fundació Privada Institut D'Investigatió Oncológica De Vall Hebron (VHIO), Fundacio Privada Institut De Recerca Hospital Universitari Vall Hebron (Ir-Huvh)
InventorsJoan Seoane Suarez, Silvia Penuelas Prieto, José Baselga Torres
Estimating the term…
The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.
A method for treating glioma in a subject in need thereof, comprising administering a therapeutically effective amount of a neutralizing antibody that specifically binds leukemia inhibitory factor (LIF);
Dependencies are inferred from the claim text.